Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy

Nephrology Dialysis Transplantation

Volumn 28, Issue 8, 2013, Pages 2116-2122

  Gremmel, Thomas ^a   Müller, Markus ^a   Steiner, Sabine ^a   Seidinger, Daniela ^a   Koppensteiner, Renate ^a   Kopp, Christoph W ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angioplasty; Antiplatelet therapy; Aspirin; Chronic kidney disease; Clopidogrel

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA;

ANTICOAGULANT THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STENT; THROMBOCYTE ACTIVATION; TREATMENT RESPONSE;

ANGIOPLASTY; ANTIPLATELET THERAPY; ASPIRIN; CHRONIC KIDNEY DISEASE; CLOPIDOGREL;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ATHEROSCLEROSIS; BLOOD PLATELET DISORDERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STENTS;

EID: 84884557023     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft103     Document Type: Article

References (36)

1. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med 2001; 345: 494-502
2. Price MJ, Endemann S, Gollapudi RR et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a pointof-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000
3. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175
4. Valgimigli M, Campo G, de Cesare N et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation 2009; 119: 3215-3222
5. Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750
6. Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933
7. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362
8. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375
9. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260
10. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-235
11. Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235
12. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965
13. Chen WH, Lee PY, Ng W et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126
14. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850
15. Fox CS, Muntner P, Chen AY et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010; 121: 357-365
16. Surana SP, Riella LV, Keithi-Reddy SR et al. Acute coronary syndrome in ESRD patients. Kidney Int 2009; 75: 558-562
17. Stigant C, Izadnegahdar M, Levin A et al. Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era. Am J Kidney Dis 2005; 45: 1002-1009
18. Patel UD, Ou FS, Ohman EM et al. Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes. Am J Kidney Dis 2009; 53: 426-437
19. Angiolillo DJ, Bernardo E, Capodanno D et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55: 1139-1146
20. Woo JS, Kim W, Lee SR et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J 2011; 162: 1018-1025
21. Muller C, Caillard S, Jesel L et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis 2012; 59: 777-785
22. Gremmel T, Kopp CW, Seidinger D et al. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity. Atherosclerosis 2009; 207: 608-613
23. Linnemann B, Schwonberg J, Mani H et al. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008; 6: 677-683
24. Holme PA, Orvim U, Hamers MJ et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997; 17: 646-653
25. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-315
26. Gremmel T, Steiner S, Seidinger D et al. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res 2011; 128: 352-357
27. Harrison P, Frelinger AL, III, Furman MI et al. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120: 323-336
28. von Beckerath N, Pogatsa-Murray G, Wieczorek A et al. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006; 95: 910-911
29. Marcucci R, Gori AM, Paniccia R et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-242
30. Geisler T, Langer H, Wydymus M et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425
31. Morel O, El Ghannudi S, Jesel L et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011; 57: 399-408
32. Geisler T, Grass D, Bigalke B et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61
33. Frelinger AL, Li Y, Linden MD et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6: 2035-2044
34. Frelinger AL III, Michelson AD, Wiviott SD et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219-226
35. Erlinge D, Varenhorst C, Braun OO et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968-1977
36. Park KW, Park JJ, Jeon KH et al. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovasc Ther 2012; 30: 5-11